Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Tarsus Pharmaceuticals has entered into a definitive agreement to acquire Alkeus Pharmaceuticals for approximately $450 million upfront. This acquisition will bolster Tarsus' retina portfolio by adding gildeuretinol, currently in phase 3 trials for Stargardt disease. The deal includes milestone payments and royalties based on sales of the therapy. The transaction is expected to close in 2026.
Company Information
Company
Tarsus Pharmaceuticals
Location
Irvine, California, United States
About
Tarsus Pharmaceuticals, Inc. is a company specializing in biological products. They have shown substantial growth and have strategic initiatives in place, including the recent appointment of Dr. Elizabeth Yeu as the new Chief Medical Officer.
Irvine